Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish Vellanki, speaks about Rain Therapeutics’ internal growth potential as well as the effect that its new treatment Rain-32 will have. Vellanki states that Rain-32 has been seen to triple or quadruple the survival time of patients with difficult to treat cancer. Rain Therapeutics is continuing to build a pipeline of targeted cancer therapies. Tune in to find out more.